What is HC Wainwright’s Forecast for CMPX FY2024 Earnings?

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Stock analysts at HC Wainwright raised their FY2024 EPS estimates for shares of Compass Therapeutics in a report released on Tuesday, November 12th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($0.36) per share for the year, up from their prior forecast of ($0.42). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.42) per share. HC Wainwright also issued estimates for Compass Therapeutics’ Q4 2024 earnings at ($0.11) EPS, FY2025 earnings at ($0.33) EPS, FY2026 earnings at ($0.29) EPS and FY2027 earnings at $0.09 EPS.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03.

Several other equities research analysts also recently weighed in on CMPX. Leerink Partners downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $5.00 to $4.00 in a report on Friday. LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a research note on Monday, September 16th. Finally, Wedbush reissued an “outperform” rating and set a $8.00 price target on shares of Compass Therapeutics in a report on Wednesday, August 7th.

Compass Therapeutics Trading Down 13.2 %

Shares of CMPX stock opened at $1.38 on Friday. The company has a market capitalization of $189.87 million, a P/E ratio of -3.73 and a beta of 0.92. The business’s 50 day moving average is $1.75 and its two-hundred day moving average is $1.42. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.34.

Hedge Funds Weigh In On Compass Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Bleakley Financial Group LLC purchased a new stake in Compass Therapeutics during the first quarter worth about $80,000. Renaissance Technologies LLC lifted its position in shares of Compass Therapeutics by 99.7% during the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after acquiring an additional 70,200 shares during the period. Rhumbline Advisers boosted its stake in shares of Compass Therapeutics by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock worth $132,000 after acquiring an additional 12,315 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Compass Therapeutics by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock worth $8,221,000 after acquiring an additional 71,008 shares during the period. Finally, Panagora Asset Management Inc. purchased a new position in Compass Therapeutics in the 2nd quarter valued at approximately $68,000. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.